RxDoctor Payments Data

David Warner, MD

Hematology & Oncology · Ann Arbor, MINPI 1407266208

Payments from drug & device makers

$2,714in general payments, 2019–2025

Across 26 payments — averaging $104.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Springworks Therapeutics, Inc.$2K
  • Daiichi Sankyo Inc.$176
  • Gilead$122
  • Bristol Myers Squibb$53
  • E.r. Squibb & Sons, L.L.C.$46
  • Novartis$43
  • plus $203 from 9 others

What the payments were for

  • Consulting fees$2,07076%
  • Food & beverage$61823%
  • Education$261%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,714 in reported general payments places this provider in the 50th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,473,850
Medicare patients
326
Services billed
79,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SprycelDasatinib15$275,075
Lenalidomide12$134,651
Abiraterone Acetate50$77,147
Imatinib Mesylate14$62,732
ZelborafVemurafenib11$62,542
EliquisApixaban17$14,350
Tamoxifen Citrate85$2,675
Hydroxyurea33$1,194
Anastrozole41$695
Morphine Sulfate ErMorphine Sulfate11$413
Dexamethasone27$390
Gabapentin19$341
Ondansetron Hcl18$271
Oxycodone Hcl13$209
Prednisone53$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel$46$275,07515 claims
PfizerEliquis$19$14,35017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →